FDA panel to weigh Myozyme expansion

The FDA questions whether a study submitted by Genzyme is strong enough to merit expanded approval of a drug to treat a rare illness known as Pompe disease; the drug, Myozyme, is up for advisory committee discussion tomorrow. Report